Webinar: Use of the XETA in the assessment strategy of the ECHA/EFSA guidance on endocrine disruptors
1 February 2021, 00.00 (CET)
Online
Webinar| 01 February 2021, 15.00-16.00
Agenda here
Summary
The aims of the webinar were to:
- Inform participants that an annex to the ECHA/EFSA guidance on the hazard identification of endocrine disruptors, focusing on the use of the Xenopus Eleutheroembryonic Thyroid Assay (XETA) as an alternative to the Amphibian Metamorphosis Assay (AMA), will be published shortly;
- Present principles and limitations of the XETA test guideline;
- Clarify when and how the XETA may be used as an alternative to the AMA in the assessment strategy of the ECHA/EFSA guidance for sufficiently investigating endocrine activity through the thyroid modality;
- Clarify how to conclude or follow-up when a XETA is available and is positive or negative.
During the webinar, the presenters gave oral answers to written questions submitted by participants. All the questions and responses have been collected and will be published shortly in a technical report together with the comments received during the ad-hoc consultation on the draft annex.
Presentation and recording
EFSA Channel YouTube video: video recording
Presentation:
Use of the XETA in the assessment strategy of the ECHA/EFSA Guidance on Endocrine Disruptors